Circassia completes ragweed vaccine study

Circassia Ltd of the UK has completed a Phase 2 study of its T-cell vaccine for ragweed allergy showing a significant reduction in symptoms, the company said. The company is backed by venture capital with Imperial Innovations holding 18.4%.